Brief: AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics
02/10/2026 07:41
BRIEF-AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics Oct 2 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA PLC - AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY
ASTRAZENECA - PHASE III TRIAL TO BEGIN IN FIRST-LINE TRIPLE-NEGATIVE BREAST CANCER
ASTRAZENECA - EACH COMPANY TO CONTRIBUTE MEDICINE FOR COMBINATION TRIALS
ASTRAZENECA - CO, DAIICHI SANKYO, SUMMIT TO CONTRIBUTE TO TRIAL COSTS AND RETAIN RIGHTS
Source text: ID:nRSB3872Xa
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)